Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
-
1041
-
1042
-
1043
-
1044
-
1045
-
1046
-
1047
-
1048
-
1049
-
1050
-
1051
ANOM analysis of evaluated criteria K1–K5.
Published 2024“…The presented research works with five criteria, identified by the Institute for Economic and Social Reforms, and aims to quantify the agreement of the results of the assessment of the financial health of territorial self-government entities in 2020 using the TOPSIS technique with a gradually decreasing number of criteria. …”
-
1052
-
1053
-
1054
Image 7_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1055
Image 6_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1056
Image 3_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1057
Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1058
Image 2_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1059
Image 4_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1060
Image 8_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”